Steroids Can Be Stopped in Some Older Myeloma Patients Steroids Can Be Stopped in Some Older Myeloma Patients
In intermediate-fit elderly patients newly diagnosed with multiple myeloma, dexamethasone can be stopped during maintenance without having an adverse effect on outcome.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Sarclisa (isatuximab-irfc) in Combination with Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 31, 2021 Category: Drugs & Pharmacology Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
Progression - free, three - year overall survival similar for lenalidomide maintenance regimen without dexamethasone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 24, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Journal, Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
WEDNESDAY, March 24, 2021 -- Dose/schedule-adjusted lenalidomide-dexamethasone (Rd) followed by a maintenance regimen of lenalidomide 10 mg/day without dexamethasone (Rd-R) is feasible for older patients with multiple myeloma (MM), with survival... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2021 Category: Pharmaceuticals Source Type: news

New figures show dexamethasone treatment for COVID-19 has so far saved 22,000 lives in UK, NHS England (published 23rd March 2021)
These figures were released by NHS England, who noted dexamethasone has also saved ~1 million lives worldwide since the positive findings from RECOVERY trial of decreased risk of death by a third in patients on ventilators and by almost a fifth in those on oxygen. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 24, 2021 Category: Consumer Health News Source Type: news

COVID treatment developed in the NHS saves a million lives
Dexamethasone, an inexpensive and widely available steroid, has saved around one million lives worldwide since its discovery as an effective treatment for COVID-19 in a clinical trial in the NHS. (Source: NHS Networks)
Source: NHS Networks - March 23, 2021 Category: UK Health Source Type: news

Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
CORK, IRELAND, March 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented positive long-term data from the global Phase 3b trial of the first complete, long-acting (LA), two-drug injectable regimen (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The 96-week findings of the Antiretroviral Therapy as Long-Acting Suppression Every 2 Months (ATLAS-2M) trial confirmed the primary endpoint, met at Week 48, and met the secondary endpoint, showing efficacy of both month...
Source: Johnson and Johnson - March 6, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months
TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen’s long-acting rilpivirine and ViiV Healthcare’s cabotegravir). The sNDA seeks to expand the CABENUVA label to include administration every two months for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per mL) on a sta...
Source: Johnson and Johnson - February 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

DEX Blunts Postspinal Hypotension in Geriatric Patients DEX Blunts Postspinal Hypotension in Geriatric Patients
Might dexamethasone be effective in in preventing or decreasing the incidence of post-spinal anesthesia hypotension in elderly patients?BMC Anesthesiology (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 24, 2021 Category: Orthopaedics Tags: Anesthesiology Journal Article Source Type: news

UK Interim Clinical Commissioning Policy for tocilizumab has been updated to cover a wider group of hospitalised COVID-19 positive patients, DHSC
NHS trusts/health boards are recommended to consider prescribing single dose of tocilizumab to eligible hospitalised patients with COVID-19 pneumonia, typically as adjuvant treatment to dexamethasone as standard of care, following announcement of findings of RECOVERY trial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 19, 2021 Category: Consumer Health News Source Type: news

COVID-19 Pandemic has Shown Humanity at its Best – & at its Worst
A health worker at a local health centre in Kinshasa, Democratic Republic of the Congo, prepares a vaccine injection. The dispatch of millions of COVID-19 vaccines to Africa started in February. Credit: UNICEF/Sibylle DesjardinsBy Tedros Adhanom GhebreyesusGENEVA, Feb 11 2021 (IPS) WHO and UNICEF have a long, deep and very special relationship. Neither of us could do what we do without the other. UNICEF’s success is WHO’s success, and we are proud to be your partner on so many issues: Ebola, polio, maternal health, nutrition, infection prevention and control, primary health care – the list is long. Neve...
Source: IPS Inter Press Service - Health - February 11, 2021 Category: International Medicine & Public Health Authors: Tedros Adhanom Ghebreyesus Tags: Development & Aid Education Global Globalisation Headlines Health Inequity Poverty & SDGs TerraViva United Nations Source Type: news

Oral Mosapride as Anti-emetic Following General Anesthesia Oral Mosapride as Anti-emetic Following General Anesthesia
Might the addition of prophylactic oral mosapride to a protocol including dexamethasone and ondansetron further reduce postoperative nausea and vomiting after general anesthesia?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 2, 2021 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holde...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 20, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Covid Deaths Lowered in Trial of Tocilizumab and Sarilumab
The big dip in mortality shown in the trial of about 800 patients has caught some experts by surprise because previous studies of the drugs showed little benefit. (Source: NYT Health)
Source: NYT Health - January 8, 2021 Category: Consumer Health News Authors: Katherine J. Wu Tags: Clinical Trials Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) medRxiv Dexamethasone (Drug) Research Immune System Deaths (Fatalities) your-feed-healthcare Source Type: news

Dexamethasone Harmful in Chronic Subdural Hematoma Dexamethasone Harmful in Chronic Subdural Hematoma
The steroid, which is commonly used as a treatment for chronic subdural hematoma, appears to be doing more harm than good in this indication, a new randomized trial has shown.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 7, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Dexamethasone Not Favored for Chronic Subdural Hematoma
Dexamethasone worse than placebo with respect to favorable outcome at six months (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 30, 2020 Category: Cancer & Oncology Tags: Neurology, Oncology, Pharmacy, Surgery, Journal, Source Type: news

Dexamethasone Not Favored for Chronic Subdural Hematoma
WEDNESDAY, Dec. 30, 2020 -- Dexamethasone results in fewer favorable outcomes than placebo among patients with symptomatic chronic subdural hematoma, according to a study published online Dec. 16 in the New England Journal of Medicine. Peter J.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 30, 2020 Category: Pharmaceuticals Source Type: news

The breakthrough medicines that could change the course of Covid
Dexamethasone demonstrates power of large-scale, randomised trials in finding effective medicinesCoronavirus – latest updatesSee all our coronavirus coverageIt remains one of the most dramatically successful outcomes in the battle against Covid-19. A cheap treatment for inflammation was found to save lives of seriously ill patients while a trio of much-touted therapies were shown to have no effect.It is now estimated that the discovery of the effectiveness of the drug dexamethasone has saved around 650,000 lives across the world, according to Professor Martin Landray, a founder of the Recovery programme – the w...
Source: Guardian Unlimited Science - December 27, 2020 Category: Science Authors: Robin McKie Observer Science Editor Tags: Coronavirus Medical research Biology UK news Infectious diseases Health World news Science Society Source Type: news

Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma
Investigators found that baseline dexamethasone use was associated with poor overall survival (OS) in glioblastoma patients receiving anti –PD-1 or anti–PD-L1 therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Bill Gates Thinks About the State of the Fight Against COVID-19
Bill Gates isn’t about to be contemplating his touchdown dance yet. You don’t get to devote your life to battling the world’s most intractable problems by declaring victory before a fight is over. But in a letter Gates released this morning, headlined, “These breakthroughs will make 2021 better than 2020,” it’s clear that the co-director of the Bill and Melinda Gates Foundation is feeling pretty sanguine about the year ahead—particularly when it comes to COVID-19. The Gates letter, which comes a month before the expected January release of Melinda Gates’s Annual Letter, sees ...
Source: TIME: Health - December 22, 2020 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news

Covid Guide: How to Get Through the Pandemic
Times are tough now, but the end is in sight. If we hunker down, keep our families safe during the holidays and monitor our health at home, life will get better in the spring. Here ’s how to get through it. (Source: NYT Health)
Source: NYT Health - December 19, 2020 Category: Consumer Health News Authors: Tara Parker-Pope Tags: Coronavirus Risks and Safety Concerns Disease Rates Chronic Condition (Health) Coronavirus (2019-nCoV) Dexamethasone (Drug) Telemedicine Vaccination and Immunization Travel Warnings Tests (Medical) Protective Clothing and Gear Winter ( Source Type: news

FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Dexamethasone Therapy Poses High Risk for Patients With Chronic Subdural Hematoma Dexamethasone Therapy Poses High Risk for Patients With Chronic Subdural Hematoma
Treating chronic subdural hematoma with dexamethasone may do more harm than good, producing less favorable outcomes and more side effects than placebo, according to a new U.K. study that randomized 748 patients.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 17, 2020 Category: Surgery Tags: Internal Medicine News Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Special Topics - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Operations - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS: Journal of Emergency Medical Services News - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Latest News - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Administration and Leadership - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Patient Care - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Extraction with an electric motor-driven handpiece may still cause subcutaneous emphysema - A case report
This article reported a case of SE around the paraorbital and submandibular regions through extractions of teeth 28 and 38. This 20-year-old man came to the emergency room at night with the major complaint of pain and discomfort during swallowing. Sudden swelling at his left face during extractions of teeth 28 and 38 three hours ago was mentioned. The original surgeon who performed the odontectomy was aware of the SE after removing the surgical drape and specific post-operation instructions were given as follows: immediate hospital care may be needed if the patient encountered difficulties in swallowing or any worsen compl...
Source: Dental Technology Blog - December 14, 2020 Category: Dentistry Source Type: news

Covid Patient Study Shows Some Benefit From an Arthritis Drug
Baricitinib had previously attracted some scrutiny from experts, who were unsure when it would most help their patients. (Source: NYT Health)
Source: NYT Health - December 13, 2020 Category: Consumer Health News Authors: Katherine J. Wu Tags: Dexamethasone (Drug) Remdesivir (Drug) Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Clinical Trials Steroids New England Journal of Medicine your-feed-healthcare Source Type: news

Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma
The subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone showed significant improvement in progression-free survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
Subcutaneous daratumumab plus pomalidomide and dexamethasone reduces risk of progression, death in relapsed/refractory MM (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 8, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
TUESDAY, Dec. 8, 2020 -- For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2020 Category: Pharmaceuticals Source Type: news

Baricitinib: Doctors Are Skeptical of This Covid-19 Drug From Eli Lilly
Baricitinib, an arthritis drug made by Eli Lilly, may reduce recovery time by a day, but costs about $1,500 and comes with side effects. (Source: NYT Health)
Source: NYT Health - December 4, 2020 Category: Consumer Health News Authors: Katherine J. Wu Tags: Dexamethasone (Drug) Medical Devices Drugs (Pharmaceuticals) Clinical Trials Research Steroids Source Type: news

Dexamethasone May Curb Efficacy of Immune Checkpoint Blockade in Glioblastoma Dexamethasone May Curb Efficacy of Immune Checkpoint Blockade in Glioblastoma
Dexamethasone given to combat cerebral edema in patients with glioblastoma may negatively affect immunotherapy, according to work in mice and clinical data.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Dexamethasone May Hinder Immunotherapy for Glioblastoma
THURSDAY, Dec. 3, 2020 -- For patients with glioblastoma (GBM) receiving immune checkpoint inhibitors, concurrent dexamethasone is associated with worse survival, according to a study published online Nov. 25 in Clinical Cancer Research. J. Bryan... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2020 Category: Pharmaceuticals Source Type: news

The effect of oral dexamethasone administration on testosterone levels in combat veterans with or without a history of suicide attempt - Sher L, Bierer LM, Makotkine I, Yehuda R.
In this study, we examined morning baseline free and total testosterone levels... (Source: SafetyLit)
Source: SafetyLit - December 1, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Immune checkpoint inhibitor efficacy against glioblastoma may decrease with dexamethasone
(American Association for Cancer Research) Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 25, 2020 Category: International Medicine & Public Health Source Type: news

COVID-19 therapy: corticosteroids including dexamethasone and hydrocortisone
In accordance with World Health Organization (WHO) recommendations, systemic corticosteroids should be used in patients with severe and critical COVID-19 disease, but not in patients with non-severe C (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 20, 2020 Category: Drugs & Pharmacology Source Type: news

Triplet Therapy Slows Refractory Multiple Myeloma
WEDNESDAY, Nov. 18, 2020 -- A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet. Sebastian Grosicki,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 therapy: corticosteroids including dexamethasone and hydrocortisone, NHS England
In accordance with World Health Organization (WHO) recommendations, this letter explains that systemic corticosteroids should be used in patients with severe and critical COVID-19 disease, but not in patients with non-severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 17, 2020 Category: Consumer Health News Source Type: news

Cytokine storms play a limited role in moderate-to-severe COVID-19
Rather than life-threatening hyperinflammation, most adults with moderate-to-severe COVID-19 have a suppressed viral immune response when compared to adults with another viral respiratory infection, influenza. St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis led research that suggests most COVID-19 patients are not candidates for treatment with steroids such as dexamethasone. (Source: World Pharma News)
Source: World Pharma News - November 16, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA Allows Emergency Use of Antibody Drug to Fight COVID-19
(WASHINGTON) — U.S. health officials have allowed emergency use of the first antibody drug to help the immune system fight COVID-19, an experimental approach against the virus that has killed more than 238,000 Americans. The Food and Drug Administration on Monday cleared the experimental drug from Eli Lilly for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. It’s a one-time treatment given through an IV. The therapy is still undergoing additional testing to establish its safety and effectiveness. It is similar to a treatment President Donald Trump received after contracting the...
Source: TIME: Health - November 10, 2020 Category: Consumer Health News Authors: Matthew Perrone / AP Tags: Uncategorized COVID-19 overnight wire Source Type: news

New discovery may change how dexamethasone is prescribed for some COVID-19 patients
(DOE/Argonne National Laboratory) New insights into the way the body distributes dexamethasone could mean that patients with high blood sugar may see diminished effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2020 Category: International Medicine & Public Health Source Type: news